Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Theoretical and Natural Science
Vol. 22, 20 December 2023
Open
Access | Article
Exploring the cooperation between rehabilitation medicine and CAR-T cell therapy for enhanced cancer treatment
* Author to whom correspondence should be addressed.
Abstract
The most common cause of death worldwide is cancer, and the sophisticated and aggressive medications used to treat it can have serious side effects and limitations. Immunotherapy known as chimeric antigen receptor T-cell (CAR-T) therapy has become a viable treatment option for some cancers, notably hematologic malignancies. However, it is linked to a number of adverse effects that may have a detrimental influence on patients' quality of life and access to care. Because it focuses on recovering patients' functional abilities and enhancing their quality of life rehabilitation medicine is essential to the treatment of cancer. This literature review aims to explore the cooperation between them to achieve better cancer treatment outcomes. This literature review will analyze and evaluate the literature on side effects of CAR-T Cell Therapy, the role of rehabilitation medicine in cancer treatment, and the rationale behind combining these two approaches for improved cancer treatment.
Keywords
rehabilitation medicine, CAR-T cell therapy, physical therapy
References
1. Firestein, H. (2022). The Role of Physical Therapy Following CAR T-Cell Therapy: A Case Report. Journal of Acute Care Physical Therapy, 13(3), 152-158.
2. Fediw, M., & Lau, K. (2021). Novel Cancer Therapeutics and Implications for Rehabilitation. Current Physical Medicine and Rehabilitation Reports, 1-6.
3. Maude, S. L., et al. (2014). Chimeric antigen receptor T cells for sustained remissions in leukemia. New England Journal of Medicine, 371(16), 1507-1517.
4. Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F. L., ... & Shpall, E. J. (2018). Chimeric antigen receptor T-cell therapy—assessment and management of toxicities. Nature Reviews Clinical Oncology, 15(1), 47-62.
5. Brudno, J. N., & Kochenderfer, J. N. (2016). Toxicities of chimeric antigen receptor T cells: recognition and management. Blood, 127(26), 3321-3330.
6. Gust, J., Hay, K. A., Hanafi, L. A., Li, D., Myerson, D., Gonzalez-Cuyar, L. F., ... & Maloney, D. G. (2017). Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discovery, 7(12), 1404-1419.
7. Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., ... & Mackall, C. L. (2014). Current concepts in the diagnosis and management of cytokine release syndrome. Blood, 124(2), 188-195.
8. Silver, J. K., Baima, J., & Mayer, R. S. (2013). Impairment-driven cancer rehabilitation: An essential component of quality care and survivorship. CA: A Cancer Journal for Clinicians, 63(5), 295-317.
9. Mustian, K. M., Alfano, C. M., Heckler, C., Kleckner, A. S., Kleckner, I. R., Leach, C. R., ... & Miller, S. M. (2017). Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: A meta-analysis. JAMA Oncology, 3(7), 961-968.
10. Pergolotti, M., Deal, A. M., Lavery, J., Reeve, B. B., & Muss, H. B. (2015). The prevalence of potentially modifiable functional deficits and the subsequent use of occupational and physical therapy by older adults with cancer. Journal of Geriatric Oncology, 6(3), 194-201.
11. Alfano, C. M., & Cheville, A. L. (2018). Integrating rehabilitation into the cancer care continuum. American Society of Clinical Oncology Educational Book, 38, 807-817
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the 3rd International Conference on Biological Engineering and Medical Science
- ISBN (Print)
- 978-1-83558-217-6
- ISBN (Online)
- 978-1-83558-218-3
- Published Date
- 20 December 2023
- Series
- Theoretical and Natural Science
- ISSN (Print)
- 2753-8818
- ISSN (Online)
- 2753-8826
- DOI
- 10.54254/2753-8818/22/20230947
- Copyright
- 20 December 2023
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited